192869-49-1

Usage

Uses

Used in Pharmaceutical Research:
tert-Butyl 7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate is used as a research compound for exploring its potential pharmaceutical applications. Its unique structure and properties make it a promising candidate for drug development, particularly in the discovery of new therapeutic agents.
Used in Drug Development:
In the pharmaceutical industry, tert-Butyl 7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate is utilized as a precursor or intermediate in the synthesis of novel drug molecules. Its chemical properties allow for further modification and optimization to enhance its therapeutic potential and efficacy.
Used in Medicinal Chemistry:
tert-Butyl 7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate serves as a valuable tool in medicinal chemistry for the design and synthesis of new chemical entities. Its structural features can be exploited to create innovative compounds with improved pharmacological properties and selectivity.
Used in Biochemical Studies:
tert-Butyl 7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate can be employed in biochemical research to investigate its interactions with various biological targets, such as enzymes, receptors, or other proteins. Understanding these interactions can provide insights into its potential therapeutic mechanisms and guide further optimization for specific applications.

InChI:InChI=1/C12H17N3O2/c1-12(2,3)17-11(16)15-5-4-10-9(7-15)6-13-8-14-10/h6,8H,4-5,7H2,1-3H3

Upstream product

• 1310796-19-0 (Z)-3-((dimethylamino)methylene)-4-oxopiperidine-1-carboxylic acid tert-butyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 1202645-17-7 3-dimethylaminomethylene-4-oxo-piperidine-1-carboxylic acid tert-butyl ester 
• 3473-63-0 formamidine acetic acid 

Relevant academic research and scientific papers

Compound as potassium channel modulator

The invention relates to a compound as a potassium channel modulator, which is a compound of a formula (I) or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof is effective for curing and preventing diseases and symptoms influenced by the activity of potassium ion channels.

AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia

Compounds of formula I, STR1whereinR 1 represents C 1-4 alkoxy optionally substituted by one or more fluorine atoms;R 2 represents H or C 1-6 alkoxy optionally substituted by one or more fluorine atoms;R 3 represents a 5- or 6-membered heterocyclic ring, the ring being optionally substituted;R 4 represents a 4-, 5-, 6-, or 7-membered heterocyclic ring, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring, the ring system as a whole being optionally substituted;X represents CH or N; andL is absent,or represents a cyclic group of formula Ia, STR2or represents a chain of formula Ib, STR3and pharmaceutically acceptable salts thereof, are useful in therapy, in particular in the treatment of benign prostatic hyperplasia.